🎧 Prefer to listen?
You lost weight on Ozempic. But you also lost bone and muscle.
You stepped on the scale. The number went down. Your doctor congratulated you. Your friends noticed. You felt great.
But something else was happening underneath. Something your scale can’t measure.
Every pound you lost wasn’t just fat. Some of it was muscle. Some of it was bone density. And if you’re a woman over 35, that matters more than you think.
The weight loss nobody talks about
GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro), and others — work. The weight loss is real. People are losing 15-20% of their body weight.
But here’s what the clinical trials showed and nobody emphasized:
A systematic review published in Expert Opinion on Pharmacotherapy found that up to 40% of weight lost on semaglutide is lean mass — not fat [1]. Lean mass means muscle and connective tissue. The stuff that keeps your metabolism running, your bones strong, and your body functional.
A 2026 study in Diabetes, Obesity and Metabolism confirmed it: patients on semaglutide lost significant fat mass, but also lost measurable lean mass and saw changes in muscle function [2].
That’s not a side effect. That’s a tradeoff nobody explained to you.
Why bone loss matters more than you think
Here’s where it gets worse — especially for women.
A narrative review in Calcified Tissue International examined the relationship between GLP-1 drugs and bone health. The findings were mixed but concerning: while some studies showed a protective effect in animal models, human data showed bone turnover markers shifted unfavorably in several trials [3].
Translation: your bones may be breaking down faster than they’re rebuilding while you’re on these drugs.
For women already at risk of osteoporosis — which includes every woman approaching menopause — this isn’t a minor concern. Bone density loss accelerates after menopause. Adding a drug that may compound that loss is a conversation your doctor should have had with you.
A 2025 review in Diabetes, Obesity and Metabolism concluded that the effects of anti-obesity medications on bone metabolism need “rigorous long-term monitoring” [4]. The key word is long-term. We don’t have 10-year data yet.
The muscle-bone connection
Muscle and bone aren’t separate systems. They talk to each other. When you lose muscle, your bones get weaker signals to stay strong. When bones weaken, your muscles have less to anchor to.
This is called the “muscle-bone unit.” And GLP-1 drugs disrupt both sides of it simultaneously.
A study in Molecular Metabolism found that blocking certain receptors could preserve muscle mass during GLP-1 treatment — but that’s still experimental [5]. Right now, the standard Ozempic protocol doesn’t include any muscle or bone preservation strategy.
You lose weight. You lose muscle. You lose bone. And nobody prescribed you anything to prevent it.
What you can actually do about it
This isn’t anti-GLP-1. These drugs help people who need them. But if you’re on one — or considering one — here’s what the research says you should add:
1. Resistance training (non-negotiable)
A study in Diabetes Care found that resistance exercise during GLP-1 treatment could optimize body composition — meaning you keep more muscle and lose more fat [6].
This isn’t optional. If you’re on Ozempic and not lifting weights, you’re accelerating muscle loss.
2. Creatine monohydrate
Creatine isn’t just for bodybuilders. A growing body of evidence shows it helps preserve lean mass during caloric restriction and supports bone density.
If you’re not taking creatine, this is the single most evidence-backed supplement for muscle and bone protection. Creatine Monohydrate Powder →
3. Collagen peptides
Your bones are about 30% collagen. As GLP-1 drugs shift bone turnover markers, supplemental collagen may help support the rebuilding side of the equation.
4. Magnesium
Magnesium is involved in over 300 enzymatic reactions — including bone mineralization and muscle function. It also regulates vitamin D activation, which you need to absorb calcium.
The bottom line
GLP-1 drugs are powerful tools. But they’re not free. The cost isn’t just the monthly prescription — it’s the muscle and bone you may be quietly losing while the scale moves in the right direction.
If you’re on one, ask your doctor about a DEXA scan. Ask about resistance training. Ask about creatine and collagen. Don’t wait for a fracture to have the conversation.
Your future self will thank you.
Coming tomorrow: Why your “healthy” smoothie might be spiking your cortisol
FTC Disclosure: This post contains affiliate links to Amazon. If you purchase through these links, I may earn a small commission at no extra cost to you. I only recommend products I’ve personally researched.
References
Bikou A et al. “A systematic review of the effect of semaglutide on lean mass: insights from clinical trials.” Expert Opin Pharmacother. 2024. https://pubmed.ncbi.nlm.nih.gov/38629387/
Alissou M et al. “Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study.” Diabetes Obes Metab. 2026. https://pubmed.ncbi.nlm.nih.gov/41068996/
Herrou J et al. “Narrative Review of Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Health in People Living with Obesity.” Calcif Tissue Int. 2024. https://pubmed.ncbi.nlm.nih.gov/37999750/
Anastasilakis AD et al. “The effects of anti-obesity medications on bone metabolism: A critical appraisal.” Diabetes Obes Metab. 2025. https://pubmed.ncbi.nlm.nih.gov/40555693/
Nunn E et al. “Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism.” Mol Metab. 2024. https://pubmed.ncbi.nlm.nih.gov/38218536/
Locatelli JC et al. “Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?” Diabetes Care. 2024. https://pubmed.ncbi.nlm.nih.gov/38687506/